

NOTIFICATION AND FORM FOR ADVANCE VOTING

by postal voting in accordance with section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of shareholders' meetings in companies and other associations.

To be received by SynAct Pharma AB no later than Thursday 20 May 2021.

The shareholder set out below hereby notifies the company of its participation and exercises its voting right for all of the shareholder's shares in SynAct Pharma AB, Reg. No. 559058-4826, at the annual general meeting on Friday 21 May 2021. The voting right is exercised in accordance with the voting options marked in Schedule 1 below.

Name of the shareholder:	Personal identification number or corporate registration number:
--------------------------	--

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions.

Assurance (if the undersigned represents the shareholder by proxy): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked.

Place and date:	
Signature:	
Clarification of signature:	
Telephone number:	E-mail:

If issued by a legal entity, the form must be signed by authorized representative(s) and be accompanied by a registration certificate or, concerning foreign legal entities, corresponding documents evidencing the authorized representative(s) of the shareholder. The same applies if the shareholder votes in advance through a proxy.

The form, and a copy of the registration certificate or corresponding documents (if applicable) shall be sent to SynAct Pharma AB, Medicion Village, Scheelevägen 2, SE-223 81 Lund, Sweden, or via e-mail to: joo@synactpharma.com. The completed form must be submitted to SynAct Pharma AB no later than on Thursday 20 May 2021.

In Schedule 1, the votes shall be set forth. A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. Only one form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The latest form received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered. For complete proposals for resolutions, please refer to the notice of the annual general meeting and the complete proposals, available on the company's website (www.synactpharma.com).

Should you have any questions, please contact SynAct Pharma AB via e-mail address joo@synactpharma.com or phone number +45 28 44 75 67. For information on how your personal data is processed, see <https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf>.

Please note that submitting this form will be regarded as giving notice of your attendance at the meeting. Please note that a prerequisite for an advance vote to be taken into account is that the shareholder who has cast the vote is registered in his/her own name in the share register kept by Euroclear Sweden AB prior to the meeting. Further instructions on this can be found in the notice to the annual general meeting.

This form for advance voting may be revoked by written notice to SynAct Pharma AB on the address above or via e-mail to joo@synactpharma.com, no later than Thursday 20 May 2021.

Schedule 1 follow on the next page

Schedule 1 – Voting form for advance voting at annual general meeting in Syn-Act Pharma AB on 21 May 2021

The voting alternatives below refer, unless otherwise stated in the form, to the proposals stated in the notice to the annual general meeting.

1. Election of Chairman of the meeting	Yes <input type="checkbox"/>	No <input type="checkbox"/>
2. Preparation and approval of the register of voters	Yes <input type="checkbox"/>	No <input type="checkbox"/>
3. Approval of the agenda	Yes <input type="checkbox"/>	No <input type="checkbox"/>
4. Election of one or two persons to confirm the minutes	Yes <input type="checkbox"/>	No <input type="checkbox"/>
5. Determination as to whether the meeting has been duly convened	Yes <input type="checkbox"/>	No <input type="checkbox"/>
7. Resolutions		
a) regarding adoption of the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet	Yes <input type="checkbox"/>	No <input type="checkbox"/>
b) regarding allocation of the company's profits in accordance with the adopted balance sheet	Yes <input type="checkbox"/>	No <input type="checkbox"/>
c) regarding discharge of the members of the board of directors and the CEO from liability		
i. Jeppe Øvlesen (as CEO)	Yes <input type="checkbox"/>	No <input type="checkbox"/>
ii. Torbjørn Bjerke	Yes <input type="checkbox"/>	No <input type="checkbox"/>
iii. John Haurum	Yes <input type="checkbox"/>	No <input type="checkbox"/>
iv. Thomas Jonassen	Yes <input type="checkbox"/>	No <input type="checkbox"/>
v. Terje Kalland	Yes <input type="checkbox"/>	No <input type="checkbox"/>
vi. Uli Hacksell	Yes <input type="checkbox"/>	No <input type="checkbox"/>
8. Determination of		
a) the number of members of the board of directors and deputy members	Yes <input type="checkbox"/>	No <input type="checkbox"/>
b) the number of auditors and deputy auditors	Yes <input type="checkbox"/>	No <input type="checkbox"/>
9. Determination of		
a) remuneration for the members of the board of directors	Yes <input type="checkbox"/>	No <input type="checkbox"/>
b) remuneration for the auditors	Yes <input type="checkbox"/>	No <input type="checkbox"/>
10. Election of members of the board of directors and Chairman of the board of directors		
a) Torbjørn Bjerke (re-election)	Yes <input type="checkbox"/>	No <input type="checkbox"/>
b) John Haurum (re-election)	Yes <input type="checkbox"/>	No <input type="checkbox"/>
c) Thomas Jonassen (re-election)	Yes <input type="checkbox"/>	No <input type="checkbox"/>
d) Terje Kalland (re-election)	Yes <input type="checkbox"/>	No <input type="checkbox"/>
e) Uli Hacksell (re-election)	Yes <input type="checkbox"/>	No <input type="checkbox"/>
f) Marina Bozilenko (new election)	Yes <input type="checkbox"/>	No <input type="checkbox"/>
g) Chairman of the board of directors: Torbjørn Bjerke (re-election)	Yes <input type="checkbox"/>	No <input type="checkbox"/>
11. Election of auditor	Yes <input type="checkbox"/>	No <input type="checkbox"/>
12. Resolution on instruction and charter for the Nomination Committee	Yes <input type="checkbox"/>	No <input type="checkbox"/>

13. Resolution on guidelines for remuneration to senior executives	Yes <input type="checkbox"/>	No <input type="checkbox"/>
14. Resolution on authorization for the board of directors regarding issues	Yes <input type="checkbox"/>	No <input type="checkbox"/>

The shareholder wishes that resolution(s) under one or several items in the form shall be deferred to a continued shareholders' meeting
(completed only if the shareholder has such a wish)

List item or items (use numbers):
